MEDIFAST INC
Close on Oct 19, 2026
- Market cap
- $133.95M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 2, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | During market hours | $76.40M | $-0.28 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | During market hours | $76.00M | $-0.19 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 17, 2026 | During market hours | $75.10M | $-1.65 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | During market hours | $89.40M | $-0.21 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | During market hours | $105.60M | $0.22 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 28, 2025 | During market hours | $115.70M | $-0.07 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 18, 2025 | During market hours | $119.00M | $0.07 | $0.10 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | During market hours | $140.20M | $0.10 | $0.35 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 29, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 3, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| loss per sharenon-GAAP | third quarter 2026 | $-0.65 to $-0.15 | New |
| loss per share | full year 2026 | $-1.75 to $-0.25 | Raised |
| revenue | full year 2026 | $270.00M to $300.00M | Maintained |
| revenue | third quarter 2026 | $60.00M to $80.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Medifast filed with the SEC
Medifast Announces Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System
Regulation FD disclosure · EX-99.1 to Form 8-K
Chief Executive Officer & Board Chairman
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.2 to Form 8-K
Medifast Announces First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces Cooperation Agreement with Steamboat Capital
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Medifast Announces Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces Third Quarter 2024 Financial Results
Agreement terminated · Results of operations · EX-99.1 to Form 8-K
Medifast Announces Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast Announces Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Medifast Announces Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Medifast Enhances “Fuel for the Future” Program to Position the Business for Long-term Sustainable Growth
Regulation FD disclosure · EX-99.1 to Form 8-K
Medifast Announces First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Medifast Announces Fourth Quarter and Full Year 2022
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Medifast Announces Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Medifast Announces Second Quarter 2022 Financial Results and
Results of operations · EX-99 to Form 8-K
Medifast, Inc. Announces Quarterly Dividend
Executive or director change · Shareholder vote results · Other events · EX-99 to Form 8-K
Medifast, Inc. Announces $100M Accelerated Share Repurchase Program
Other events · EX-99.1 to Form 8-K
Medifast, Inc. Announces First Quarter 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Medifast, Inc. Announces Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Medifast, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medifast, Inc. Announces Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K